Assuring Viral Safety of the Biopharmaceutical Process
26:11
Challenge for Industry with new USP (665) / (1665)
30:49
Viral Clearance: Removal of Viral Contamination in Biopharmaceutical Manufacturing
27:14
Viral Clearance: A WuXi Advanced Therapies Perspective
31:23
Leachable Risk Assessment Approaches:
29:33
Good Identification Practices in Non-Targeted Screening Analyses
1:37:34
The Cancer Expert: "This Common Food Is Making Cancer Worse!"
46:14
Toxicological Safety Assessment of Process Equipment-Related Leachables in the context of USP (665)
20:29